These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 37242793)
1. Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population. Lim A; Sharma P; Stepanov O; Reddy VP Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242793 [TBL] [Abstract][Full Text] [Related]
2. Opportunities and Challenges for PBPK Model of mAbs in Paediatrics and Pregnancy. Gill KL; Jones HM AAPS J; 2022 Jun; 24(4):72. PubMed ID: 35650328 [TBL] [Abstract][Full Text] [Related]
3. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents. Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129 [TBL] [Abstract][Full Text] [Related]
4. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel. Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234 [TBL] [Abstract][Full Text] [Related]
5. Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague. Nguyen D; Shaik JS; Tai G; Tiffany C; Perry C; Dumont E; Gardiner D; Barth A; Singh R; Hossain M Br J Clin Pharmacol; 2022 Feb; 88(2):416-428. PubMed ID: 34289143 [TBL] [Abstract][Full Text] [Related]
6. Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. Abduljalil K; Jamei M; Rostami-Hodjegan A; Johnson TN AAPS J; 2014 May; 16(3):568-76. PubMed ID: 24700271 [TBL] [Abstract][Full Text] [Related]
7. A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab. Chang HP; Shakhnovich V; Frymoyer A; Funk RS; Becker ML; Park KT; Shah DK Br J Clin Pharmacol; 2022 Jan; 88(1):290-302. PubMed ID: 34189743 [TBL] [Abstract][Full Text] [Related]
8. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children. Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38782791 [TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim. Basu S; Lien YTK; Vozmediano V; Schlender JF; Eissing T; Schmidt S; Niederalt C Front Pharmacol; 2020; 11():868. PubMed ID: 32595502 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study. Willmann S; Thelen K; Kubitza D; Lensing AWA; Frede M; Coboeken K; Stampfuss J; Burghaus R; Mück W; Lippert J Thromb J; 2018; 16():32. PubMed ID: 30534008 [TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic modelling of semaglutide in children and adolescents with healthy and obese body weights. Machado TR; Honorio T; Souza Domingos TF; Candido de Paula DDS; Cabral LM; Rodrigues CR; Abrahim-Vieira BA; Teles de Souza AM Br J Clin Pharmacol; 2023 Oct; 89(10):3175-3194. PubMed ID: 37293836 [TBL] [Abstract][Full Text] [Related]
12. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model. Vogt W Clin Pharmacokinet; 2014 Jan; 53(1):51-72. PubMed ID: 23839530 [TBL] [Abstract][Full Text] [Related]
13. Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics. Adiwidjaja J; Boddy AV; McLachlan AJ Front Pharmacol; 2019; 10():1672. PubMed ID: 32082165 [TBL] [Abstract][Full Text] [Related]
14. Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example. Feng S; Shi J; Parrott N; Hu P; Weber C; Martin-Facklam M; Saito T; Peck R Clin Pharmacokinet; 2016 Jul; 55(7):823-832. PubMed ID: 26715215 [TBL] [Abstract][Full Text] [Related]
15. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563 [TBL] [Abstract][Full Text] [Related]
16. Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment. Peigné S; Bouzom F; Brendel K; Gesson C; Fouliard S; Chenel M J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):13-27. PubMed ID: 26563503 [TBL] [Abstract][Full Text] [Related]